| High‐density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy SY Kim, M Yu, EE Morin, J Kang, MJ Kaplan, A Schwendeman Arthritis & rheumatology 72 (1), 20-30, 2020 | 67 | 2020 |
| Biosimilarity under stress: a forced degradation study of Remicade® and Remsima™ K Pisupati, A Benet, Y Tian, S Okbazghi, J Kang, M Ford, S Saveliev, ... MAbs 9 (7), 1197-1209, 2017 | 48 | 2017 |
| Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres T Li, A Chandrashekar, A Beig, J Walker, JKY Hong, A Benet, J Kang, ... European Journal of Pharmaceutics and Biopharmaceutics 158, 401-409, 2021 | 30 | 2021 |
| Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function J Kang, SY Kim, D Vallejo, TS Hageman, DR White, A Benet, J Coghlan, ... European Journal of Pharmaceutics and Biopharmaceutics 146, 111-124, 2020 | 29 | 2020 |
| Collision-induced unfolding reveals stability differences in infliximab therapeutics under native and heat stress conditions DD Vallejo, J Kang, J Coghlan, CR Ramírez, DA Polasky, RT Kurulugama, ... Analytical Chemistry 93 (48), 16166-16174, 2021 | 27 | 2021 |
| Characterization of apolipoprotein A-Ipeptide phospholipid interaction and its effect on HDL nanodisc assembly. H Patel, B Ding, K Ernst, L Shen, W Yuan, J Tang, D Lindsey, J Kang, ... International Journal of Nanomedicine 14, 3069-3086, 2019 | 27 | 2019 |
| Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars J Kang, T Halseth, D Vallejo, ZI Najafabadi, KI Sen, M Ford, BT Ruotolo, ... Analytical and bioanalytical chemistry 412, 763-775, 2020 | 25 | 2020 |
| Infliximab biosimilars in the age of personalized medicine J Kang, K Pisupati, A Benet, BT Ruotolo, SP Schwendeman, ... Trends in biotechnology 36 (10), 987-992, 2018 | 16 | 2018 |
| The effects of pH and excipients on exenatide stability in solution A Benet, T Halseth, J Kang, A Kim, R Ackermann, S Srinivasan, ... Pharmaceutics 13 (8), 1263, 2021 | 13 | 2021 |
| Applicability of non-halogenated methyl propionate to microencapsulation J Kang, E Sah, H Sah Journal of Microencapsulation 31 (4), 323-332, 2014 | 9 | 2014 |
| Physicochemical characterization and functionality comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab) JL Kinzer, TA Halseth, J Kang, SY Kim, P Kumaran, M Ford, S Saveliev, ... International Journal of Pharmaceutics 635, 122646, 2023 | 4 | 2023 |
| Phospholipids impact the protective effects of HDL-mimetic nanodiscs against lipopolysaccharide-induced inflammation SY Kim, J Kang, MV Fawaz, M Yu, Z Xia, EE Morin, L Mei, K Olsen, XA Li, ... Nanomedicine 18 (29), 2127-2142, 2023 | 2 | 2023 |
| Utilization of catalytic hydrolysis of ethyl acetate for solvent removal during microencapsulation M Lee, J Kang, H Sah Journal of microencapsulation 30 (4), 346-355, 2013 | 1 | 2013 |
| The Effects of pH and Excipients on Exenatide Stability in Solution. Pharmaceutics 2021, 13, 1263 A Benet, T Halseth, J Kang, A Kim, R Ackermann, S Srinivasan, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Analytical Comparability Strategies for Originators and Biosimilars J Kang | | 2019 |
| Optimization of Apolipoprotein A-1 Mimetic Peptides for Lipid Binding and Lecithin-cholesterol Acyltransferase Activation FM Acevedo-Mariani, J Kang, W Yuan, I Pogozheva, A Schwendeman Arteriosclerosis, Thrombosis, and Vascular Biology 36 (suppl_1), A223-A223, 2016 | | 2016 |
| Finding New Non-halogenated Solvent Useful for Preparation of PLGA Microspheres J Kang, E Sah, H Sah | | |
